Thymic stromal lymphopoietin: a promising therapeutic target for allergic diseases

Int Arch Allergy Immunol. 2013;160(1):18-26. doi: 10.1159/000341665. Epub 2012 Aug 30.

Abstract

Thymic stromal lymphopoietin (TSLP), an interleukin 7-like cytokine, can trigger dendritic cell (DC)-mediated T-helper type 2 (Th2) inflammatory responses. Recent evidence demonstrates that cytokines TSLP and OX40 (CD134)/OX40 ligand seem to be important players in the maintenance of Th2 memory pool in the pathogenesis of asthma. Accumulating data reveal that the pathogenic T cells involved in asthma are likely to be inflammatory Th2 cells. TSLP is involved in the development of asthma through crosstalk with nuclear factor NF-ĸB. Progression of skin fibrosis in atopic dermatitis occurs via TSLP/TSLP receptor. TSLP-mediated dermal inflammation aggravates experimental allergic asthma. Also, TSLP polymorphisms are associated with susceptibility to asthma, atopic dermatitis, and eczema herpeticum. These findings suggest a master switch of TSLP in the initiation of allergic and adaptive inflammation through innate pathways at the epithelial cell-DC interface. The TSLP pathway is therefore a promising target for immunotherapy of allergic diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Asthma / immunology*
  • Asthma / metabolism
  • Asthma / therapy
  • Cytokines / genetics
  • Cytokines / immunology*
  • Cytokines / metabolism*
  • Dendritic Cells / immunology*
  • Humans
  • Hypersensitivity / immunology*
  • Hypersensitivity / metabolism
  • Hypersensitivity / therapy
  • Inflammation / immunology
  • Inflammation Mediators / immunology
  • OX40 Ligand / immunology
  • OX40 Ligand / metabolism
  • Th2 Cells / immunology*
  • Thymic Stromal Lymphopoietin

Substances

  • Cytokines
  • Inflammation Mediators
  • OX40 Ligand
  • TNFSF4 protein, human
  • Thymic Stromal Lymphopoietin